✦ LIBER ✦

Inhibition of histamine methylation in vivo by the Dimaprit analog, SKF compound 91488

✍ Scribed by Michael A. Beaven; Richard E. Shaff

Publisher: SP Birkhäuser Verlag Basel
Year: 1979
Tongue: English
Weight: 451 KB
Volume: 9
Category: Article
ISSN: 1420-908X
DOI: 10.1007/bf01968110

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Growth inhibition of hepatocellular carc

Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79

✍ Teresa Kosakowska-Cholody; Wieslaw M. Cholody; Humcha K. Hariprakasha; Anne Monk 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 671 KB

Inhibition of NADH oxidation by 1-methyl

Inhibition of NADH oxidation by 1-methyl-4-phenylpyridinium analogs as the basis for the prediction of the inhibitory potency of novel compounds

✍ Sablin, Sergey O. ;Krueger, Matthew J. ;Yankovskaya, Victoria L. ;Tkachenko, Ser 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 901 KB

Grb2-associated binder-1 plays a central

Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5

✍ Ziqiu Wang; Lisheng Ge; Meifang Wang; Brian I. Carr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 711 KB

Compound 5 (Cpd 5), a K vitamin analog, has been shown to inhibit Hep3B human hepatoma cell growth in cultures and rat hepatoma growth in vivo through prolonged epidermal growth factor receptor (EGFR)-extracellular response kinase (ERK) phosphorylation, and hepatocyte growth factor (HGF) synergizes

Inhibition of histamine release induced

Inhibition of histamine release induced by compound 48/80 and peptide 401 in the presence and absence of calcium. Implications for the mode of action of anti-allergic compounds

✍ Madeleine Ennis; Gordon Atkinson; Frederick L. Pearce 📂 Article 📅 1980 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 524 KB

Inhibition of the growth of caki-I human

Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II

✍ Andreas Jungwirth; Andrew V. Schally; Gabor Halmos; Kate Groot; Karoly Szepeshaz 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

## Background: Metastatic or recurrent renal cell carcinoma (rcc) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. no uniformly effective therapeutic agents are available for the management of patients with rcc. hormones and growth factors may play a rol